{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:29:27Z","timestamp":1778131767548,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Autologous hematopoietic stem cell transplantation is an effective therapeutic option for patients with treatment-refractory multiple sclerosis (MS) and may be considered as first line treatment in aggressive forms. Currently, a variety of conditioning and serotherapy regimens are employed across transplant centers. In this study, we compared immune reconstitution at days 30 and 100 post-transplant in MS patients undergoing AHSCT with cyclophosphamide-based conditioning, combined with in vivo T-cell depletion using either polyclonal rabbit anti-thymocyte globulin (ATG; Thymoglobulin, Genzyme-Sanofi) or rabbit anti-T-lymphocyte globulin (ATLG; Grafalon, Neovii). We observed a significantly faster immune reconstitution for CD3\n                    <jats:sup>+<\/jats:sup>\n                    , CD3\n                    <jats:sup>+<\/jats:sup>\n                    HLA-DR\n                    <jats:sup>+<\/jats:sup>\n                    , CD3\n                    <jats:sup>+<\/jats:sup>\n                    CD4\n                    <jats:sup>+<\/jats:sup>\n                    , CD4\n                    <jats:sup>+<\/jats:sup>\n                    CD45RA\n                    <jats:sup>+<\/jats:sup>\n                    , CD4\n                    <jats:sup>+<\/jats:sup>\n                    CD45RO\n                    <jats:sup>+<\/jats:sup>\n                    , CD3\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    , CD8\n                    <jats:sup>+<\/jats:sup>\n                    CD45RA\n                    <jats:sup>+<\/jats:sup>\n                    , CD8\n                    <jats:sup>+<\/jats:sup>\n                    CD45RO\n                    <jats:sup>+<\/jats:sup>\n                    , and CD4\n                    <jats:sup>+<\/jats:sup>\n                    CD25\n                    <jats:sup>+<\/jats:sup>\n                    CD127low cells in patients receiving ATLG compared to ATG at day 30 post-transplant. Although infections resulting in rehospitalization by day 180 were similarly distributed between groups, viral reactivations occurred exclusively in patients receiving ATG. No sign of high grade infectious complications or death was noted.\n                  <\/jats:p>","DOI":"10.1038\/s41409-025-02730-y","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T12:53:12Z","timestamp":1764247992000},"page":"172-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of anti-human T cell globulins on immune reconstitution and early infections after autologous transplant in patients with multiple sclerosis"],"prefix":"10.1038","volume":"61","author":[{"given":"Johanna","family":"Richter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Fischbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Rathje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena Kristina","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Fehse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Badbaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna Carolina","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeny","family":"Klyuchnikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Wolschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherina","family":"Lueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-1847","authenticated-orcid":false,"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel A.","family":"Friese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Heesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2730_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41583-024-00823-z","volume":"25","author":"MS Woo","year":"2024","unstructured":"Woo MS, Engler JB, Friese MA. The neuropathobiology of multiple sclerosis. Nat Rev Neurosci. 2024;25:493\u2013513.","journal-title":"Nat Rev Neurosci"},{"key":"2730_CR2","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41409-022-01702-w","volume":"57","author":"T Alexander","year":"2022","unstructured":"Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2022;57:1055\u201362.","journal-title":"Bone Marrow Transpl"},{"key":"2730_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"B Sharrack","year":"2019","unstructured":"Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transpl. 2019;55:283.","journal-title":"Bone Marrow Transpl"},{"key":"2730_CR4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/bmt.2011.185","volume":"47","author":"JA Snowden","year":"2011","unstructured":"Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2011;47:770.","journal-title":"Bone Marrow Transpl"},{"key":"2730_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41582-024-01050-x","volume":"21","author":"PA Muraro","year":"2025","unstructured":"Muraro PA, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder\u2014recommendations from ECTRIMS and the EBMT. Nat Rev Neurol. 2025;21:140\u201358.","journal-title":"Nat Rev Neurol"},{"key":"2730_CR6","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/ene.14324","volume":"27","author":"G Boffa","year":"2020","unstructured":"Boffa G, Lapucci C, Sbragia E, Varaldo R, Raiola AM, Curr\u00f2 D, et al. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. Eur J Neurol. 2020;27:2047\u201355.","journal-title":"Eur J Neurol"},{"key":"2730_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/acn3.51366","volume":"8","author":"V H\u00e4u\u00dfler","year":"2021","unstructured":"H\u00e4u\u00dfler V, Ufer F, P\u00f6ttgen J, Wolschke C, Friese MA, Kr\u00f6ger N, et al. aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis. Ann Clin Transl Neurol. 2021;8:1269\u201378.","journal-title":"Ann Clin Transl Neurol"},{"key":"2730_CR8","doi-asserted-by":"crossref","unstructured":"Braun B, Fischbach F, Richter J, Pfeffer LK, Fay H, Reinhardt S, et al. Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: sustained improvement in cognition and quality of life. Mult Scler Relat Disord. 2024;82. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38176284\/.","DOI":"10.1016\/j.msard.2023.105414"},{"key":"2730_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/08916930802197081","volume":"41","author":"S Abrahamsson","year":"2008","unstructured":"Abrahamsson S, Muraro PA. Immune re-education following autologous hematopoietic stem cell transplantation. Autoimmunity. 2008;41:577\u201384.","journal-title":"Autoimmunity"},{"key":"2730_CR10","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","volume":"21","author":"M Mohty","year":"2007","unstructured":"Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387\u201394.","journal-title":"Leukemia"},{"key":"2730_CR11","doi-asserted-by":"crossref","unstructured":"Ismail A, Nitti R, Sharrack B, Badoglio M, Ambron P, Labopin M, et al. ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP). Bone Marrow Transplant. 2024;59. Available from https:\/\/pubmed.ncbi.nlm.nih.gov\/39143182\/.","DOI":"10.1038\/s41409-024-02383-3"},{"key":"2730_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jviromet.2011.08.022","volume":"178","author":"F Gatto","year":"2011","unstructured":"Gatto F, Cassina G, Broccolo F, Morreale G, Lanino E, Di Marco E, et al. A multiplex calibrated real-time PCR assay for quantitation of DNA of EBV-1 and 2. J Virol Methods. 2011;178:98\u2013105.","journal-title":"J Virol Methods"},{"key":"2730_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1089\/152581601750289028","volume":"10","author":"B Fehse","year":"2001","unstructured":"Fehse B, Chukhlovin A, K\u00fchlcke K, Marinetz O, Vorwig O, Renges H, et al. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res. 2001;10:419\u201325.","journal-title":"J Hematother Stem Cell Res"},{"key":"2730_CR14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/ajh.27619","volume":"100","author":"AB Notarantonio","year":"2025","unstructured":"Notarantonio AB, Morisset S, Piucco R, P\u00e9r\u00e8s M, Boulang\u00e9 L, Alitcher A, et al. Differential clinical and immunological impacts of anti-T-lymphocyte globulin (ATLG) vs. anti-thymocyte globulin (ATG) in preventing graft-versus-host disease post-allogeneic hematopoietic stem cell transplantation: a comparative study. Am J Hematol. 2025;100:626.","journal-title":"Am J Hematol"},{"key":"2730_CR15","unstructured":"Nirmal G, Kharya G, Shankar R, Singh S, Paul S, Choudhary M, et al. A comparative analysis of low dose grafalon\u00ae versus thymoglobuline\u00ae as serotherapy in hematopoietic stem cell transplant in pediatric and young adult population. Pediatr Hematol Oncol. 2024; Available from https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/08880018.2024.2398523."},{"key":"2730_CR16","doi-asserted-by":"crossref","unstructured":"Oostenbrink LVE, Jol-Van Der Zijde CM, Kielsen K, Jansen-Hoogendijk AM, Ifversen M, M\u00fcller KG, et al. Differential elimination of anti-thymocyte globulin of Fresenius and genzyme impacts T-cell reconstitution after hematopoietic stem cell transplantation. Front Immunol. 2019;10. Available from https:\/\/pubmed.ncbi.nlm.nih.gov\/30894854\/.","DOI":"10.3389\/fimmu.2019.00315"},{"key":"2730_CR17","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00432-014-1742-z","volume":"140","author":"A Mensen","year":"2014","unstructured":"Mensen A, Na IK, H\u00e4fer R, Meerbach A, Schlecht M, Pietschmann ML, et al. Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD. J Cancer Res Clin Oncol. 2014;140:1971\u201380.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2730_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1179\/102453309X12583347113852","volume":"15","author":"K Terasako","year":"2010","unstructured":"Terasako K, Sato K, Sato M, Kimura SI, Nakasone H, Okuda S, et al. The effect of different ATG preparations on immune recovery after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia. Hematology. 2010;15:165\u20139.","journal-title":"Hematology"},{"key":"2730_CR19","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1111\/ajt.12514","volume":"13","author":"I Popow","year":"2013","unstructured":"Popow I, Leitner J, Grabmeier-Pfistershammer K, Majdic O, Zlabinger GJ, Kundi M, et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J Transpl. 2013;13:3103\u201313.","journal-title":"Am J Transpl"},{"key":"2730_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3324\/haematol.2012.067611","volume":"98","author":"IK Na","year":"2013","unstructured":"Na IK, Wittenbecher F, Dziubianau M, Herholz A, Mensen A, Kunkel D, et al. Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica. 2013;98:23\u201330.","journal-title":"Haematologica"},{"key":"2730_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1084\/jem.20041679","volume":"201","author":"PA Muraro","year":"2005","unstructured":"Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201:805.","journal-title":"J Exp Med"},{"key":"2730_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/B978-0-323-90242-7.00003-1","volume":"202","author":"A Mariottini","year":"2024","unstructured":"Mariottini A, Cencioni MT, Muraro PA. Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis. Handb Clin Neurol. 2024;202:55\u201374.","journal-title":"Handb Clin Neurol"},{"key":"2730_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/jnnp-2018-319446","volume":"90","author":"JJ Moore","year":"2019","unstructured":"Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Hendrawan K, et al. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:514\u201321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2730_CR24","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/S0301-472X(03)00204-2","volume":"31","author":"E Meijer","year":"2003","unstructured":"Meijer E, Cornelissen JJ, L\u00f6wenberg B, Verdonck LF. Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell\u2014depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol. 2003;31:1026\u201330.","journal-title":"Exp Hematol"},{"key":"2730_CR25","doi-asserted-by":"crossref","unstructured":"Kazmi M, Muraro PA, Mehra V, Gabriel I, De Matteis E, Brittain G, et al. Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: a 20-year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT). Br J Haematol. 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/40500866\/.","DOI":"10.1111\/bjh.20199"},{"key":"2730_CR26","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1097\/01.TP.0000065737.60591.9D","volume":"75","author":"E Meijer","year":"2003","unstructured":"Meijer E, Bloem AC, Dekker AW, Verdonck LF. Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell-depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts. Transplantation. 2003;75:1910\u20133.","journal-title":"Transplantation"},{"key":"2730_CR27","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41409-022-01666-x","volume":"57","author":"R Massoud","year":"2022","unstructured":"Massoud R, Klyuchnikov E, Gagelmann N, Zabelina T, Wolschke C, Ayuk F, et al. Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation. Bone Marrow Transpl. 2022;57:1548\u201355.","journal-title":"Bone Marrow Transpl"},{"key":"2730_CR28","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00277-025-06267-4","volume":"104","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhou Y, Zhao K, Cui J, Zhang X, Wen R, et al. Comparison of ATG-thymoglobulin with atg-fresenius in patients with hematological malignancies who undergo allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis. Ann Hematol. 2025;104:1907.","journal-title":"Ann Hematol"},{"key":"2730_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3324\/haematol.2016.148510","volume":"102","author":"F Baron","year":"2017","unstructured":"Baron F, Mohty M, Blaise D, Soci\u00e9 G, Labopin M, Esteve J, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:224\u201334.","journal-title":"Haematologica"},{"key":"2730_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00277-020-04014-5","volume":"99","author":"L Zhou","year":"2020","unstructured":"Zhou L, Gao Zyong, Lu DP. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience. Ann Hematol. 2020;99:1389.","journal-title":"Ann Hematol"},{"key":"2730_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1526513","volume":"16","author":"I Falicovich","year":"2025","unstructured":"Falicovich I, Nachmias B, Elias S, Zimran E, Shaulov A, Stepensky P, et al. Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin. Front Immunol. 2025;16:1526513.","journal-title":"Front Immunol"},{"key":"2730_CR32","doi-asserted-by":"crossref","unstructured":"Song T, Yin S, Li X, Jiang Y, Lin T. Thymoglobulin vs. ATG-Fresenius as induction therapy in kidney transplantation: a Bayesian network meta-analysis of randomized controlled trials. Front Immunol. 2020;11. Available from https:\/\/pubmed.ncbi.nlm.nih.gov\/32318057\/.","DOI":"10.3389\/fimmu.2020.00457"},{"key":"2730_CR33","doi-asserted-by":"publisher","first-page":"e0165233","DOI":"10.1371\/journal.pone.0165233","volume":"11","author":"F Burkhalter","year":"2016","unstructured":"Burkhalter F, Schaub S, Bucher C, G\u00fcrke L, Bachmann A, Hopfer H, et al. A comparison of two types of rabbit antithymocyte globulin induction therapy in immunological high-risk kidney recipients: a prospective randomized control study. PLoS ONE. 2016;11:e0165233.","journal-title":"PLoS ONE"},{"key":"2730_CR34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/01.TP.0000116442.81259.60","volume":"77","author":"D Ducloux","year":"2004","unstructured":"Ducloux D, Kazory A, Challier B, Coutet J, Bresson-Vautrin C, Motte G, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation. 2004;77:1029\u201333.","journal-title":"Transplantation"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02730-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02730-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02730-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:03:25Z","timestamp":1771283005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02730-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2730"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02730-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}